Biomedical Engineering Reference
In-Depth Information
Narayanan S, Desiraju R, Chintagunta P (2004) ROI implications for pharmaceutical promotional
expenditures: the role of marketing mix interactions. J Mark 68(4):90-105
Nerlove M, Arrow KJ (1962) Optimal advertising policy under dynamic conditions. Economica
(New Series) 29(114):129-142
Neslin S (2001) ROI Analysis of Pharmaceutical Promotion (RAPP): an independent study.
www.
rappstudy.org
. Accessed 10 Dec 2003
Palumbo FB, Daniel Mullins C (2002) The development of direct-to-consumer prescription drug
advertising regulation. Food Drug Law J 57(3):423-443
Papp L (1997) Firms seek freedom to pitch their drugs but ad campaigns are bad for health,
researchers warn. The Toronto Star, Dec 27, p A1
Parker PM, Roller L-H (1997) Collusive conduct in duopolies: multimarket contact and cross-
ownership in the mobile telephone industry. RAND J Econ 28(2):304-322
PhRMA (2008) The facts about pharmaceutical marketing and promotion.
http://www.phrma.
Pines WL (1999) A history and perspective on direct-to-consumer promotion. Food Drug Law J
54:489-518
Reuters News (2011) Drug R&D spending fell in 2010, and heading lower, June 26, 23:00:00
Rizzo JA (1999) Advertising and competition in the ethical pharmaceutical industry: the case of
antihypertensive drugs. J Law Econ 42(1):89-116
Roehm ML, Tybout AM (2006) When will a brand scandal spill over, and how should competitors
respond? J Mark Res 43:366-373
Scherer FM (2000) The pharmaceutical industry. In: Culyer AJ, Newhouse JP (eds) Handbook of
health economics, vol 1. Elsevier, Amsterdam
Senate Bill S319 (2011) Amendment to the Federal Food, Drug, and Cosmetic Act with respect to
the importation of prescription drugs, and for other purposes. 112th Cong., 1st Sess
Sethuraman R, Tellis GJ, Briesch R (2011) How well does advertising work? Generalizations from
a meta-analysis of brand advertising elasticity. J Mark Res 28:160-174
Simonin BL, Ruth JA (1998) Is a company known by the company it keeps? Assessing the spillover
effects of brand alliances on consumer brand attitudes. J Mark Res 35:30-42
Stremersch S, Lemmens A (2009) Sales growth of new pharmaceuticals across the globe: the role
of regulatory regimes. Mark Sci 28(4):690-780
Suh J-Y, Park S-B (2009) Successful brand alliance and its negative spillover effect on a host
brand: test of cognitive responses. Adv Consum Res 36(2009):243-247
Sullivan M (1990) Measuring image spillovers in umbrella-branded products. J Bus 63(3):309-329
The Wall Street Journal (2011) Amylin, Lilly end ill-fated linkup, Nov 9, 2011
US FDA (2004) Postmarket drug safety information for patients and providers: Vioxx (rofecoxib)
questions and answers. Food and Drug Administration.
http://www.fda.gov/Drugs/DrugSafety
.
Accessed 10 Feb 2012
US Government Accountability Office (November 2006) Improvements needed in FDA's oversight
of direct-to-consumer advertising. GAO, Washington, DC
Van Everdingen Y, Fok D, Stremersch S (2009) Modeling global spillover of new product takeoff.
J Mark Res 46:637-652
Verniers I, Stremersch S, Croux C (2011) The global entry of new pharmaceuticals: a joint inves-
tigation of launch window and price. Int J Res Mark 28:295-308
Veugelers R (1998) Collaboration in R&D: an assessment of theoretical and empirical findings.
Economist 146(3):419-443
Wernerfelt B (1988) Umbrella branding as a signal of new product quality: an example of signaling
by posting a bond. RAND J Econ 19(3):458-466
Wittink DR (2002) Analysis of ROI for Pharmaceutical Promotion (ARPP).
www.rxpromoroi.org
.
Accessed 10 Dec 2003
Yang Y, Shi M, Goldfarb A (2009) Estimating the value of brand alliances in professional team
sports. Mark Sci 28(6):1095-1111
Search WWH ::
Custom Search